Interestingly, the ctDNA isolated from the blood of patients with pancreatic cancer harbors the mutated KRAS gene 25, and N-ras gene mutations have been detected in the plasma of myelodysplastic syndrome and acute myelogenous leukemia (AML) patients 26, which further underscores the utility of ctDNA as a cancer biomarker. The gene discussed is KRAS; the disease is acute myeloid leukemia.